Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts

Cohen S, Ushiro H, Stoscheck C and Chinkers M: A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J Biol Chem. 257:1523–1531. 1982.PubMed/NCBI

Carpenter G and Cohen S: Epidermal growth factor. J Biol Chem. 265:7709–7712. 1990.

Pawson T: Protein modules and signalling networks. Nature. 373:573–580. 1995. View Article : Google Scholar : PubMed/NCBI

Yasui W, Hata J, Yokozaki H, et al: Interaction between epidermal growth factor and its receptor in progression of human gastric carcinoma. Int J Cancer. 41:211–217. 1988. View Article : Google Scholar : PubMed/NCBI

Ozanne B, Richards CS, Hendler F, Burns D and Gusterson B: Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas. J Pathol. 149:9–14. 1986. View Article : Google Scholar : PubMed/NCBI

Hollstein MC, Smits AM, Galiana C, et al: Amplification of epidermal growthfactor receptor gene but no evidence of ras mutations in primary human esophageal cancers. Cancer Res. 48:5119–5123. 1988.PubMed/NCBI

Haeder M, Rotsch M, Bepler G, et al: Epidermal growth factor receptor expression in human lung cancer cell lines. Cancer Res. 48:1132–1136. 1988.PubMed/NCBI

Ritter CA and Arteaga CL: The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol. 30:3–11. 2003. View Article : Google Scholar : PubMed/NCBI

Selvaggi G, Novello S, Torri V, et al: Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small cell lung cancer. Ann Oncol. 15:28–32. 2004. View Article : Google Scholar : PubMed/NCBI

Shepherd FA, Pereira JR, Ciuleanu T, et al: Erlotinib in previously treated non-small cell lung cancer. N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI

Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 25:1960–1966. 2007. View Article : Google Scholar

Pao W, Miller VA, Politi KA, et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2:e732005. View Article : Google Scholar : PubMed/NCBI

Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007. View Article : Google Scholar : PubMed/NCBI

Tang Z, Du R, Jiang S, et al: Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer. 99:911–922. 2008. View Article : Google Scholar : PubMed/NCBI

Furugaki K, Iwai T, Shirane M, Kondoh K, Moriya Y and Mori K: Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS. Oncol Rep. 24:1141–1146. 2010. View Article : Google Scholar : PubMed/NCBI

Okabe T, Okamoto I, Tsukioka S, et al: Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification. Clin Cancer Res. 15:907–913. 2009. View Article : Google Scholar

Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J and Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 100:1701–1707. 2009. View Article : Google Scholar : PubMed/NCBI

Shi Z, Peng XX, Kim IW, et al: Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res. 67:11012–11020. 2007. View Article : Google Scholar : PubMed/NCBI